Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study

J Subst Use Addict Treat. 2023 Jun:149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30.

Abstract

Introduction: Conflictual evidence exists regarding the effects of cannabis use on the outcomes of opioid agonist therapy (OAT). In this exploratory analysis, we examined the effect of recent cannabis use on opioid use, craving, and withdrawal symptoms, in individuals participating in a trial comparing flexible buprenorphine/naloxone (BUP/NX) take-home dosing model to witnessed ingestion of methadone.

Methods: We analyzed data from a multi-centric, pragmatic, 24-week, open label, randomized controlled trial in individuals with prescription-type opioid use disorder (n = 272), randomly assigned to BUP/NX (n = 138) or methadone (n = 134). The study measured last week cannabis and opioid use via timeline-follow back, recorded at baseline and every two weeks during the study. Craving symptoms were measured using the Brief Substance Craving Scale at baseline, and weeks 2, 6, 10, 14, 18 and 22. The study measured opioid withdrawal symptoms via Clinical Opiate Withdrawal Scale at treatment initiation and weeks 2, 4, and 6.

Results: The mean maximum dose taken during the study was 17.3 mg/day (range = 0.5-32 mg/day) for BUP/NX group and 67.7 mg/day (range = 10-170 mg/day) in the methadone group. Repeated measures generalized linear mixed models demonstrated that cannabis use in the last week (mean of 2.3 days) was not significantly associated with last week opioid use (aβ ± standard error (SE) = -0.06 ± 0.04; p = 0.15), craving (aβ ± SE = -0.05 ± 0.08, p = 0.49), or withdrawal symptoms (aβ ± SE = 0.09 ± 0.1, p = 0.36). Bayes factor (BF) for each of the tested models supported the null hypothesis (BF < 0.3).

Conclusions: The current study did not demonstrate a statistically significant effect of cannabis use on outcomes of interest in the context of a pragmatic randomized-controlled trial. These findings replicated previous results reporting no effect of cannabis use on opioid-related outcomes.

Trial registration: ClinicalTrials.gov NCT03033732.

Keywords: Cannabinoid; Cannabis; Craving; Opioid use disorder; Withdrawal.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Bayes Theorem
  • Buprenorphine*
  • Buprenorphine, Naloxone Drug Combination / therapeutic use
  • Cannabis* / adverse effects
  • Humans
  • Methadone / therapeutic use
  • Narcotic Antagonists
  • Opiate Substitution Treatment / methods
  • Opioid-Related Disorders* / drug therapy
  • Substance Withdrawal Syndrome* / drug therapy

Substances

  • Analgesics, Opioid
  • Narcotic Antagonists
  • Buprenorphine
  • Buprenorphine, Naloxone Drug Combination
  • Methadone

Associated data

  • ClinicalTrials.gov/NCT03033732